Biological Therapies for Cancer: Technologies and Global Markets
상품코드:1872694
리서치사:BCC Research
발행일:2025년 11월
페이지 정보:영문 139 Pages
라이선스 & 가격 (부가세 별도)
한글목차
세계 암 생물학적 치료 시장 규모는 2025년 1,570억 달러, 예측 기간 동안 CAGR 7.5%로 성장하고, 2030년 말까지 2,250억 달러에 달할 것으로 예측되고 있습니다.
단일클론항체 부문은 2025년 881억 달러, 예측 기간 동안 CAGR 7.5%로 성장하고, 2030년 말에는 1,265억 달러에 이를 것으로 예측됩니다. CAR T 세포 치료 부문은 2025년 234억 달러, 예측 기간 동안 CAGR 7.8%로 성장하고, 2030년 말에는 341억 달러에 이를 것으로 예측됩니다.
본 보고서에서는 세계의 암 생물학적 치료 시장을 조사했으며, 시장 개요, 시장 영향요인 및 시장 기회 분석, 기술 동향, 법규제 환경, 시장 규모 추이와 예측, 각종 구분, 지역별 상세 분석, 주요 기업 프로파일 등을 정리했습니다.
목차
제1장 주요 요약
시장 전망
조사 범위
시장 요약
기술의 진보
시장 역학과 성장요인
부문 분석
결론
제2장 시장 개요
개요 및 시장 정의
주요 작용기전과 모달리티
Porter's Five Forces 분석
거시경제 요인분석
고령화가 암의 발병과 생물학적 제제 수요를 촉진
의료비와 암 치료제 지출 증가
미국 관세 시나리오의 영향
암 생물학적 제제의 가격 전략
가치 기반 가격 설정
혁신에 대한 프리미엄 가격
적응증에 근거한 가격 설정
시장 접근 및 단계적 가격 설정
경쟁 벤치마킹
암 치료제의 비용
바이오시밀러의 개요
바이오시밀러와 항암제의 비용
인도와 중국의 바이오시밀러
유럽의 바이오시밀러
바이오시밀러의 문제점
제3장 시장 역학
시장 역학
시장 성장 촉진요인
세계의 암 이환율의 상승
면역종양학과 표적요법의 진보
맞춤형 의료와 정밀의료로의 이행
시장 성장 억제요인
고액의 치료비
엄격한 제조 및 규제 요건
시장 기회
승인된 생물학적 제제의 적응 확대
바이오의약품 제조에 있어서의 기술의 진보
제4장 규제 상황
규제 시나리오
개요
미국
EU
일본
중국
인도
Medicare의 적용 범위와 상환
제5장 신기술과 개발
개요
차세대 항체 약물 복합체(ADC)
이중 특이성 항체와 다중특이성 항체
네오 안티겐과 개인화 암 백신(mRNA와 펩타이드)
동종(기성품) 세포 요법
암 생물학적 치료에서 AI
제6장 시장 세분화 분석
세분화의 내역
암 생물학적 치료 시장 분석 : 제품 유형별
단일클론항체
백신
CAR-T 세포 요법
암 증식 억제제
면역관문억제제
기타(조혈 인자, 사이토 카인)
암 생물학적 치료 시장 분석 : 암유형별
암의 유형/부위별 역학
폐암
유방암
대장암
전립선암
기타(혈액, 피부, 난소, 희소암)
지리적 내역
바이오시밀러 시장 :지역별
시장 규모와 예측
북미
유럽
아시아태평양
기타 지역
제7장 암 임상시험 및 개발 중 생물학적 제제
개요
주요 파이프라인 의약품: 기업별
제8장 경쟁 구도
개요
암 생물학적 치료 시장 : 주요 기업
제9장 부록
조사 방법
참고문헌
약어
기업 프로파일
AMGEN INC.
ASTRAZENECA
BAYER AG
BIONTECH SE
BRISTOL-MYERS SQUIBB CO.
F. HOFFMANN-LA ROCHE LTD.
GSK PLC
INCYTE
INNATE PHARMA INC.
JOHNSON & JOHNSON
LILLY USA LLC
MERCK & CO. INC.
NOVARTIS AG
PFIZER INC.
SANOFI
SHW
영문 목차
영문목차
The global biological therapies market for cancer is expected to grow from $157 billion in 2025 and is projected to reach $225 billion by the end of 2030, at a compound annual growth rate (CAGR) of 7.5% during the forecast period of 2025 to 2030.
The monoclonal antibodies segment of biological therapies market for cancer is expected to grow from $88.1 billion in 2025 and is projected to reach $126.5 billion by the end of 2030, at a CAGR of 7.5% during the forecast period of 2025 to 2030.
The CAR T-cell therapy segment of biological therapies market for cancer is expected to grow from $23.4 billion in 2025 and is projected to reach $34.1 billion by the end of 2030, at a CAGR of 7.8% during the forecast period of 2025 to 2030.
Report Scope
This report provides an overview of the global biological therapies for the cancer market and analyzes market trends. It includes global revenue ($ millions) for the base year data of 2024 and estimated data for the forecast period 2025 through 2030. The market is based on technology, application, end user, and region. The regions covered in this study include North America, Europe, Asia-Pacific, the Rest of the World, focusing on major countries in these regions.
The report also sheds light on developments related to venture capital and corporate investments, regulatory trends, and the enterprise strategies of key firms as well as potential future opportunities stemming from biological therapies for cancer of precision medicine and population genomics programs. The combination of in-depth market forecasts, macroeconomic analysis, and tariff assessments makes this report a critical resource for stakeholders, investors, and policymakers seeking to understand and take advantage of the rapidly developing biological therapies for cancer sector. The report focuses on the significant driving trends and challenges that affect the market and vendor landscape. It also analyzes emerging technologies related to the market.
The report concludes with an analysis of the competitive landscape, which provides the ranking/share of key players in the biological therapies for cancer market. It also has a dedicated section of company profiles that covers the details of key market players. For market estimates, data have been provided for 2022 and 2023 as the historic years, 2024 as the base year, and 2025-2030 for the forecast years.
Report Includes
43 data tables and 53 additional tables
An analysis of the global markets for biological therapies for cancer treatment and related technologies
Analyses of the global market trends, with revenue data for 2022-2024, estimates for 2025 and projections of compound annual growth rates (CAGRs) through 2030
Estimates of the current market size and revenue prospects for the global cancer biologics market, along with a market share analysis by product type, cancer type, and region
Facts and figures about market dynamics, opportunities and deterrents, technological advances, regulations, innovations and standards and the impacts of macroeconomic variables
Impact analysis of the U.S. tariff laws on the market
Insights derived from Porter's Five Forces model, as well as global supply chain
A look at major issues and trends related to the R&D of more effective cancer treatment, new cancer therapeutics in development and the outlook on cancer clinical trials
Key marketed drugs and recent approvals, sales statistics and past performance of the top-selling biologics and insight into their patent expiries
A relevant patent analysis, featuring key granted and published patents
Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, as well as the ESG risk ratings and practices of leading companies
Analysis of the industry structure, including companies' market shares and rankings, strategic initiatives, M&A activity and a venture funding outlook
Profiles of the leading companies, including Merck & Co. Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., AstraZeneca, and Johnson & Johnson
Table of Contents
Chapter 1 Executive Summary
Market Outlook
Scope of Report
Market Summary
Technological Advances
Market Dynamics and Growth Factors
Segmental Analysis
Conclusion
Chapter 2 Market Overview
Overview and Market Definition
Key Modalities and Mechanisms of Action
Porter's Five Forces Model
Bargaining Power of Buyers
Bargaining Power of Suppliers
Potential for New Entrants
Competition in the Industry
Threat of Substitutes
Macroeconomic Factors Analysis
Aging Population Driving Cancer Incidence and Demand for Biologics
Rising Healthcare Expenditures and Oncology Drug Spending
Impact of the U.S. Tariff Scenario
Pricing Strategies for Cancer Biologics
Value-Based Pricing
Premium Pricing for Innovation
Indication-Based Pricing
Market Access and Tiered Pricing
Competitive Benchmarking
Cancer Drug Costs
Overview of Biosimilars
Biosimilars and Costs of Cancer Drugs
Biosimilars in India and China
Biosimilars in Europe
Issues with Biosimilars
Chapter 3 Market Dynamics
Market Dynamics
Market Drivers
Rising Global Cancer Incidence
Advances in Immuno-Oncology and Targeted Therapies
Shift Towards Personalized and Precision Medicine
Market Restraints
High Treatment Costs
Stringent Manufacturing and Regulatory Requirements
Market Opportunities
Expanding Indications for Approved Biologics
Technological Advances in Biologics Manufacturing
Chapter 4 Regulatory Landscape
Biological Therapies for Cancer Industry Regulatory Scenario
Overview
U.S.
EU
Japan
China
India
Medicare Coverage and Reimbursement for Cancer Care
Chapter 5 Emerging Technologies and Developments
Overview
Next-Generation Antibody-Drug Conjugates (ADCs)
Bispecific and Multispecific Antibodies
Neoantigen and Personalized Cancer Vaccines (mRNA and Peptide)
Allogeneic ("Off-the-Shelf") Cell Therapies
Artificial Intelligence (AI) in Biological Cancer Therapies
Chapter 6 Market Segmentation Analysis
Segmentation Breakdown
Market Analysis for Biological Therapies for Cancer by Product Type
Monoclonal Antibodies
Vaccines
CAR T-cell Therapy
Cancer Growth Blockers
Immune Checkpoint Inhibitors
Other (Blood Cell Growth Factors, Cytokines)
Market Analysis of Biological Therapies for Cancer by Cancer Type
Epidemiology by Cancer Type/Site
Lung Cancer
Breast Cancer
Colorectal Cancer
Prostate Cancer
Other (Blood, Skin, Ovarian, Rare Cancer)
Geographic Breakdown
Global Biosimilars Market by Region
Market Size and Forecast
North America
Europe
Asia-Pacific
Rest of the World
Chapter 7 Cancer Clinical Trials and Biologics in Development
Overview
Key Pipeline Drugs by Company
Chapter 8 Competitive Landscape
Overview
Biological Therapy for Cancer Market: Major Players
